Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q2 FY22 Earnings Presentation
15 slides from Alembic Pharmaceuticals's earnings presentation, September 2021
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – September 2021
Alembic Pharmaceuticals Limited Investor presentation – September 2021 BSE & NSE: APLLTD
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir
Slide 3: Financial Highlights
Financial Highlights INR Bn Particulars Q2 FY22 Q2 FY21 Growth H1 FY22 H1 FY21 Growth FY21 Net Sales 12.92 14.57 -11% 26.18 27.98 -6% 53.93 EBIDTA Pre R&D 4.20 6.28 -33% 8.26 11.77 -30% 22.52 Margin % 33% 43% 32% 42% 42% R&D 1.68 1.85 -9% 3.35 3.27 2% 6.70 R&D % 13% 13% 13% 12% 12% EBIDTA Post R&D 2
Slide 4: Business snapshot – Q2FY22
Business snapshot – Q2FY22 Formulations Generics Branded API Total US Ex-US India Revenue Q2FY22 (INR Bn) 3.48 1.97 5.09 2.39 12.92 API 19% 19% 27% Vet 5% Generics 42% Q2FY22 Revenue Contribution Acute 14% 15% Branded Speciality 20% 39% Growth Q2FY22 -40% -9% -11% 0% 23% over Q2FY21 Growth Q2FY22 -6
Slide 5: Business snapshot – H1FY22
Business snapshot – H1FY22 Formulations Generics Branded API Total US Ex-US India Revenue H1FY22 (INR Bn) 7.16 3.94 9.89 5.19 26.18 API 20% 20% Vet Generics 27% 4% H1FY22 Revenue 42% Contribution Acute 14% 15% Branded Speciality 19% 38% Growth H1FY22 -39% -2% -6% 6% 37% over H1FY21 • Well-establishe
Slide 6: US Generic
US Generic INR Bn Revenue – Q2 FY22 INR Bn Revenue – Last 5 Years CAGR - 24% 19.76 21.63 5.82 12.88 3.48 9.19 9.20 Q2FY21 Q2FY22 FY17 FY18 FY19 FY20 FY21 Approved ANDAs Injectable Derma 2 17 ➢ Increase in competitive intensity during H1FY22 which has led to price erosion in some large products. Opht
Slide 7: Ex-US Generics
Ex-US Generics Revenue : Q2 FY22 INR Bn Revenue – Last 5 Years INR Bn CAGR - 25% 1.97 0% ↑ 1.97 7.79 4.94 4.97 Q2FY21 Q2FY22 ➢ The Ex-US business continuous to do well in spite of a high base last 3.20 2.86 year. ➢ The EX-US business grew at 6% during H1FY22. ➢ New launches on track to drive growth
Slide 8: API
API Revenue : Q2 FY22 INR Bn Revenue – Last 5 Years INR Bn CAGR - 11% 2.63 2.39 9.55 7.71 7.08 6.40 6.51 Q2FY21 Q2FY22 ➢ API business continues to do well. H1FY21 had a high base of Azithromycin hence business de-grew by 9% during Q2FY22. ➢ Rest of the portfolio continues to do well. ➢ The API busin
Slide 9: R&D: Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37 Filing 8.0 13.7% 14.0% Approval 13.1% 12.7% 29 30 29 12.4% 6.0 25 R&D Spend 20 19 20 18 * 11 Filings & 4.0 6.7 7 Approvals 6.5 R&D % of were 5.0 sales 2.0 4.3 4.1 contributed by 5 acquisition o
Slide 10: State of the art facilities and infrastructure
State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables Feb’21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Feb’2
Slide 11: Branded Business
Branded Business Revenue – Q2 FY22 INR Bn Revenue – Last 5 Years CAGR - 5% INR Bn 15.0 5.09 14.3 13.8 4.15 0.64 12.5 12.7 0.52 Vet 1.81 1.43 Acute Speciality 2.20 2.63 Q2FY21 Q2FY22 FY17 FY18 FY19 FY20 FY21 Marketing organization Key achievements ➢ 5000 + Marketing team ➢ 3 Brands in top 300 ➢ 18 Ma
Slide 12: Therapy-wise Performance Q2 FY22
Therapy-wise Performance Q2 FY22 Q2 FY22 Q2 FY21 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 7 1.9 5 10 15 1.9 16 12 Gastrology 15 1.5 20 16 4
Slide 13: Therapy-wise Performance H1 FY22
Therapy-wise Performance H1 FY22 H1 FY22 H1 FY21 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 13 1.8 6 11 13 1.9 14 13 Gastrology 24 1.4 29 25 -
Slide 14: Financials: Generating consistent returns
Financials : Generating consistent returns Revenue INR Bn EBIDTA Net Profit INR Bn INR Bn 53.93 16.31 11.78 46.06 39.35 12.13 8.29 31.34 31.31 8.75 5.84 6.15 6.42 4.13 4.03 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 CAGR - 15% CAGR - 28% CAGR - 31% EBIDTA margin % Cap
Slide 15: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Q2 FY22 Earnings Presentation on 6ix